Drug Development
AS PART OF THE CREATION OF INNOVATIVE MEDICINES, TECHNOLOGIES AND MEDICAL PRODUCTS WITH INTERNATIONAL STANDARDS GMP IBСH RAS DEVELOPS FINISHED PHARMACEUTICAL SUBSTANCES AND FINISHED DOSAGE FORMS FOR RELEVANT FIELDS OF MEDICINE.
PRIORITY DIRECTIONS OF DRUG DEVELOPMENT:
- COVID-19 (IBH63);
- ONCOLOGICAL DISEASES (IBH1, IBH9, IBH13.1, IBH13.2);
- METABOLIC DISORDERS (IBH5, IBH45.1, IBH45.2, IBH 45.3);
- NEUROLOGICAL DISEASES (IBH18, IBH19);
- IMMUNOLOGICAL PATHOLOGIES (IBH15, IBH20, IBH39, IBH43, IBH44, IBH57);
- INFECTIOUS DISEASES (IBH7, IBH24);
- DRUGS OF WIDE APPLICATION (IBH3, IBH4, IBH25, IBH26, IBH38);
- SENSORY DISORDERS (IBH27, IBH38);
- REGENERATIVE MEDICINE (IBH28).
